Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Quality-Adjusted Survival With First-Line Cabozantinib or Sunitinib for Advanced Renal Cell Carcinoma in the CABOSUN Randomized Clinical Trial (Alliance)Cancer 2020 Oct 06;[EPub Ahead of Print], RC Chen, TK Choueiri, M Feuilly, J Meng, J Lister, F Marteau, AD Falchook, MJ Morris, DJ George, DR Feldman
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.